



# Chemistry and Pharmacology of Anticancer Drugs

David E. Thurston



 CRC Press  
Taylor & Francis Group

---

# Contents

<b>Chapter 1</b>	<b>Introduction to Cancer</b>	<b>1</b>
1.1	Introduction	1
1.2	Terminology	1
1.3	Metastases	2
1.4	Diagnosis and Screening	3
1.5	Formation of Cancer Cells (Tumorigenesis)	4
1.6	Mechanisms of Genomic Damage	5
1.6.1	Internal Factors	5
1.6.1.1	Mutations	5
1.6.1.2	Addition or Loss of Genetic Material	5
1.6.1.3	Epigenetic Changes	5
1.6.1.4	Modified Gene Expression	7
1.6.2	External Factors	7
1.6.2.1	Viruses	7
1.6.2.2	Bacterial Infections	8
1.6.2.3	Chemicals	8
1.6.2.4	Radioactivity	10
1.6.2.5	Electromagnetic Radiation	10
1.6.2.6	Cancer Treatments	11
1.6.3	Hereditary Factors	12
1.7	Treatments	12
1.7.1	Surgery	12
1.7.2	Radiotherapy	13
1.7.3	Photodynamic Therapy (PDT)	14
1.7.4	Biological Response Modifying Agents	14
1.7.5	Chemotherapy	14
1.8	Discovery of Anticancer Drugs and Preclinical Evaluation	15
1.9	Accessibility of Drugs to Tumor Cells	17
1.10	Achieving Selective Toxicity	17
1.11	Limiting the Toxicity of Chemotherapeutic Agents	18
1.11.1	Dose Scheduling and Cell Cycle	18
1.11.2	Use of Adjuvants	20
1.11.3	Novel Formulations and Prodrugs	20
1.11.4	The Cold Cap	20
1.11.5	Pharmacogenomic Markers of Toxicity	20
1.12	Overview of Mechanisms of Action of Chemotherapeutic Agents	21
1.13	Drug Resistance	23
1.14	Combination Chemotherapy	25

1.15	Use of Adjuvants.....	26
1.16	Infertility Following Cancer Treatments .....	26
	Further Reading .....	27
<b>Chapter 2 Antimetabolites .....</b>		<b>29</b>
2.1	Introduction .....	29
2.2	DHFR Inhibitors (Antifolates).....	29
2.2.1	Methotrexate.....	29
2.3	Purine Antimetabolites .....	31
2.4	Pyrimidine Antimetabolites.....	32
2.5	Thymidylate Synthase Inhibition.....	34
2.6	Adenosine Deaminase Inhibition.....	35
2.7	Ribonucleotide Reductase Inhibition.....	35
	Further Reading .....	36
<b>Chapter 3 DNA-Interactive Agents.....</b>		<b>37</b>
3.1	Introduction .....	37
3.2	Alkylating Agents .....	38
3.2.1	Methylating Agents .....	38
3.2.1.1	Dacarbazine.....	38
3.2.1.2	Temozolomide.....	39
3.2.1.3	Procarbazine.....	43
3.2.2	Ecteinascidin-743 .....	44
3.2.3	Pyrrlobenzodiazepine (PBD) Monomers.....	45
3.3	Cross-Linking Agents .....	47
3.3.1	Nitrogen Mustards.....	49
3.3.1.1	Aliphatic Nitrogen Mustards .....	50
3.3.1.2	Aromatic Nitrogen Mustards .....	51
3.3.1.3	Oxazaphosphorines .....	52
3.3.1.4	Conjugated Nitrogen Mustards.....	54
3.3.2	Aziridines .....	56
3.3.3	Epoxides .....	57
3.3.4	Methanesulfonates.....	57
3.3.5	Nitrosoureas .....	58
3.3.5.1	Lomustine .....	59
3.3.5.2	Carmustine .....	60
3.3.6	Platinum Complexes .....	61
3.3.6.1	Cisplatin .....	62
3.3.6.2	Carboplatin.....	63
3.3.6.3	Oxaliplatin.....	63
3.3.7	Carbinolamines.....	63
3.3.8	Cyclopropanes.....	65
3.3.9	Mitomycin-C .....	65
3.3.10	Sequence-Selective DNA Cross-Linking Agents .....	66

3.3.10.1	PBD Dimers (SJG-136).....	67
3.3.10.2	Cyclopropanepyrroloindole (CPI) Dimer (Bizelesin).....	67
3.4	Intercalating Agents .....	69
3.4.1	Anthracyclines.....	71
3.4.1.1	Doxorubicin .....	71
3.4.1.2	Daunorubicin.....	73
3.4.1.3	Aclarubicin.....	73
3.4.1.4	Epirubicin.....	73
3.4.1.5	Idarubicin .....	73
3.4.2	Anthracenes.....	74
3.4.2.1	Mitoxantrone.....	74
3.4.3	Phenoxazines.....	74
3.4.3.1	Dactinomycin.....	75
3.5	Topoisomerase Inhibitors.....	76
3.5.1	Topoisomerase I Inhibitors .....	77
3.5.1.1	Topotecan.....	77
3.5.1.2	Irinotecan .....	78
3.5.2	Topoisomerase II Inhibitors.....	79
3.5.2.1	Etoposide.....	79
3.5.2.2	Teniposide.....	80
3.5.2.3	Ellipticine .....	81
3.5.2.4	Amsacrine .....	81
3.6	DNA-Cleaving Agents .....	81
3.6.1	Bleomycins.....	82
3.6.2	Enediynes .....	83
	Further Reading .....	84
<b>Chapter 4</b>	<b>Antitubulin Agents .....</b>	<b>85</b>
4.1	Introduction .....	85
4.2	Vinca Alkaloids.....	87
4.2.1	Vinblastine.....	89
4.2.2	Vincristine .....	90
4.2.3	Vindesine.....	90
4.2.4	Vinorelbine.....	90
4.3	The Taxanes .....	90
4.3.1	Paclitaxel .....	92
4.3.2	Docetaxel.....	93
	Further Reading .....	93
<b>Chapter 5</b>	<b>Molecularly Targeted Agents.....</b>	<b>95</b>
5.1	Introduction .....	95
5.2	Kinase Inhibitors.....	96
5.2.1	Classification of Protein Kinases.....	96
5.2.2	Functions of Protein Kinases.....	97

5.2.3	Mechanism of Signal Transfer.....	98
5.2.4	Regulation of Kinase Activity by Drugs .....	98
5.2.5	Role of Protein Kinases in Cancer .....	99
5.2.5.1	Mutations in Protein Kinases .....	99
5.2.5.2	Overexpression of Protein Kinases .....	100
5.2.6	Development of Inhibitors of Protein and Receptor Kinases .....	100
5.2.6.1	BCR-ABL Inhibition: Imatinib .....	100
5.2.6.2	HER2/neu Inhibition: Trastuzumab.....	102
5.2.6.3	EGFR Inhibition: Gefitinib, Erlotinib, and Cetuximab ...	103
5.2.6.4	VEGFR Inhibition .....	109
5.2.6.5	PDGFR Inhibition.....	110
5.2.6.6	Multiple Target Inhibitors.....	111
5.2.6.7	Other Potential Targets .....	112
5.3	Inhibition of <i>Ras</i> Pathway Signaling.....	114
5.3.1	Introduction .....	114
5.3.2	Mechanism of <i>Ras</i> Signaling Pathway.....	115
5.3.3	Classes of Inhibitors of Farnesyltransferase.....	116
5.3.4	Tipifarnib.....	117
5.3.5	Lonafarnib .....	118
5.3.6	BMS-214662.....	118
5.3.7	Other Novel <i>Ras</i> Pathway Inhibitors.....	119
5.4	Cell Cycle Inhibitors.....	119
5.5	Proteasome Inhibitors .....	120
5.6	mTOR Inhibitors .....	122
	Further Reading .....	125
<b>Chapter 6</b>	<b>Hormonal Therapies.....</b>	<b>127</b>
6.1	Introduction .....	127
6.2	Breast Cancer .....	127
6.2.1	Early Breast Cancer .....	127
6.2.2	Advanced Breast Cancer.....	128
6.2.3	Role of Estrogen in Tumor Growth.....	128
6.2.4	Anti-Estrogens.....	130
6.2.4.1	Tamoxifen .....	130
6.2.4.2	Toremifene .....	132
6.2.4.3	Novel Selective ER Modulators .....	132
6.2.5	Aromatase Inhibitors.....	134
6.2.5.1	Aminoglutethimide .....	136
6.2.5.2	Anastrozole .....	137
6.2.5.3	Letrozole .....	137
6.2.5.4	Vorozole .....	138
6.2.5.5	Exemestane .....	139
6.3	Prostatic Cancer .....	139
6.3.1	Gonadorelin Analogs (LH-RH Analogs; Agonists and Antagonists) .....	142

6.3.1.1	Buserelin .....	143
6.3.1.2	Goserelin .....	144
6.3.1.3	Leuprorelin Acetate .....	144
6.3.1.4	Triptorelin .....	144
6.3.2	LH-RH Receptor Antagonists .....	145
6.3.3	Anti-Androgens .....	146
6.3.3.1	Cyproterone Acetate .....	148
6.3.3.2	Flutamide .....	149
6.3.3.3	Bicalutamide .....	150
6.3.3.4	Nilutamide .....	150
6.4	Neuroendocrine Tumors: Somatostatin Analogs .....	151
6.4.1	Octreotide .....	152
6.4.2	Lanreotide .....	152
6.5	Estrogen Therapy .....	153
6.5.1	Diethylstilbestrol .....	153
6.5.2	Ethinylestradiol .....	153
6.6	Progestogen Therapy .....	154
6.6.1	Gestonorone Caproate .....	154
6.6.2	Medroxyprogesterone Acetate .....	155
6.6.3	Megestrol Acetate .....	155
6.6.4	Norethisterone .....	156
	Further Reading .....	156
:		
<b>Chapter 7</b>	<b>Tumor-Targeting Strategies .....</b>	<b>157</b>
7.1	Introduction .....	157
7.2	Antibody-Based Approaches .....	158
7.2.1	Antibodies as Single Agents .....	159
7.2.2	Antibody-Drug Conjugates .....	160
7.2.2.1	Gemtuzumab Ozogamicin .....	160
7.2.3	Antibody-Radionuclide Conjugates .....	161
7.2.3.1	Pemtumomab .....	161
7.3	Vascular-Targeting Strategies .....	162
7.3.1	Anti-Angiogenic Agents .....	164
7.3.1.1	Bevacizumab .....	164
7.3.2	Vascular Disruptive Agents (VDAs) .....	165
7.3.2.1	Combretastatins .....	165
7.3.2.2	Combretastatin Prodrugs: CA4P and Oxi4503 .....	168
7.3.2.3	Flavone-8-Acetic Acid (FAA) and DMXAA .....	168
7.3.3	Bioreductive Agents .....	170
7.3.3.1	AQ4N .....	171
7.3.4	Polymer-Drug Conjugates .....	172
7.4	X-DEPT (Biphasic) Strategies .....	173
7.4.1	ADEPT .....	174
7.4.2	GDEPT (or VDEPT) .....	176
7.4.3	PDEPT .....	178

7.5	Enzymatic Targeting .....	179
7.5.1	Prodrug Activation by Constitutively Overexpressed Tumor Enzymes .....	179
7.5.2	Cosubstrate-Mediated Prodrug Therapy .....	180
7.5.3	Asparaginase .....	182
7.6	Photoactivated Drugs (Photodynamic Therapy).....	182
7.6.1	Porfimer Sodium .....	183
7.6.2	Temoporfin .....	184
7.7	Boron Neutron Capture Therapy (BNCT).....	184
7.8	Novel Drug Delivery Approaches.....	187
7.8.1	Gene Therapy .....	187
7.8.2	Nanotechnology-Based Drug Delivery.....	188
7.8.3	Intracranial Delivery .....	189
7.8.4	Ultrasound Targeting.....	189
	Further Reading .....	191

**Chapter 8 Biological Agents..... 193**

8.1	Introduction .....	193
8.2	Biological Response Modifiers (BRMs) .....	194
8.2.1	Monoclonal Antibodies (MAbs).....	194
8.2.1.1	Rituximab.....	194
8.2.1.2	Alemtuzumab.....	194
8.2.2	Interferons .....	195
8.2.2.1	Interferon Alpha.....	195
8.2.3	Interleukins.....	196
8.2.3.1	Interleukin-2.....	196
8.3	Immunotherapy .....	196
8.3.1	BCG Bladder Instillation .....	197
8.4	Enzyme-Based Therapies.....	197
8.4.1	Asparaginase .....	198
8.5	Vaccines.....	198
8.5.1	The Immune System .....	199
8.5.2	Types of Cancer Vaccines.....	199
8.5.3	Strategies for Stimulating the Immune System.....	200
8.5.3.1	Direct Use of Tumor Antigens .....	200
8.5.3.2	Enhancement of Immunogenicity of Tumor Antigens.....	200
8.5.3.3	Primed APCs.....	201
8.5.3.4	Anti-Idiotype Antibodies .....	201
8.5.4	Manufacture of Vaccines.....	201
8.5.5	Activity of Vaccines .....	202
8.5.6	Examples of Vaccines in Development .....	202
8.5.6.1	Non-Hodgkin's Lymphoma .....	202
8.5.6.2	Non-Small-Cell Lung Cancer (NSCLC).....	203
8.5.6.3	Melanoma .....	203
8.5.6.4	Prostate Cancer .....	203

8.5.6.5	Cervical Cancer .....	203
8.5.6.6	Head and Neck and Cervical Cancer .....	203
8.5.7	Conclusion.....	204
Further Reading	.....	204
<b>Chapter 9</b>	<b>The Future .....</b>	<b>205</b>
9.1	Introduction .....	205
9.2	Novel Biological Targets and Therapeutic Strategies .....	205
9.2.1	Novel Therapeutic Targets .....	205
9.2.1.1	Resistance Inhibitors.....	205
9.2.1.2	Telomerase Inhibitors .....	209
9.2.1.3	Epigenetic-Based Therapies .....	211
9.2.1.4	Antimetastatic Agents.....	216
9.2.1.5	Heat Shock Protein (HSP) Inhibitors.....	219
9.2.1.6	Thioredoxin Reductase Inhibitors .....	222
9.2.1.7	HDM2-p53 Binding Inhibitors.....	223
9.2.1.8	Radiosensitizing Agents.....	226
9.2.2	New Biological Agents .....	227
9.2.2.1	Growth Factors .....	227
9.2.2.2	Tumor Necrosis Factor .....	228
9.2.2.3	Immunomodulation.....	228
9.2.3	Novel Drug Delivery Systems .....	229
9.2.3.1	Near-Infrared-Activated Nanoshells.....	230
9.2.3.2	Radioactive Glass Beads (Microspheres).....	231
9.2.4	Nucleic Acid Targeting .....	231
9.2.4.1	Antigene Strategy .....	233
9.2.4.2	Antisense Strategy .....	235
9.2.4.3	Ribozymes.....	236
9.2.4.4	Zinc Finger Proteins (ZFPs).....	237
9.2.4.5	GeneICE™ Technology.....	238
9.2.4.6	Decoy Strategies .....	239
9.2.4.7	RNA Interference (RNAi) .....	239
9.2.5	Gene Therapy .....	241
9.2.6	Cancer Stem Cells.....	242
9.3	New Research Tools and Methodologies .....	244
9.3.1	Gene Hunting and DNA Sequencing .....	245
9.3.2	Genomics and Proteomics .....	245
9.3.3	Protein Structural Studies .....	247
9.3.4	Chemical Technologies .....	247
9.3.5	Screening Methodologies.....	249
9.3.6	In Vivo Models.....	249
9.3.7	Sources of New Lead Molecules.....	250
9.4	Chemopreventive Agents .....	252
9.4.1	Resveratrol.....	254
9.4.2	Phytoestrogens .....	255



9.4.3	Curcumin.....	256
9.4.4	Sulforaphane.....	257
9.4.5	COX-2 Inhibitors .....	258
9.4.6	Antioxidants .....	260
9.4.6.1	Ascorbic Acid (Vitamin C).....	260
9.4.6.2	Ergothioneine.....	261
9.4.7	Olive Oil (The “Mediterranean Diet”) .....	261
9.4.7.1	Oleic Acid.....	262
9.4.7.2	Oleocanthal .....	262
9.4.7.3	Lycopene.....	263
9.4.8	The KEAP1 Gene .....	264
	Further Reading .....	265
<b>Chapter 10 Personalized Treatments .....</b>		<b>267</b>
10.1	Introduction .....	268
10.2	Screening for Risk of Disease Development.....	269
10.3	Prognosis and Staging.....	271
10.4	Screening for Risk of Recurrence of Disease .....	272
10.5	Selecting Best Treatments for Patients.....	272
10.5.1	Genomic and Proteomic Tests .....	272
10.5.2	Chemosensitivity Testing .....	273
10.6	Predicting Side Effects of Chemotherapeutic Agents .....	273
10.7	Pharmacogenomics in Clinical Trials.....	275
	Further Reading .....	276
<b>Chapter 11 Adjunct Therapies .....</b>		<b>279</b>
11.1	Introduction .....	279
11.2	Anti-Emetic Agents.....	279
11.2.1	Oral and Parenteral Dosing.....	279
11.2.2	Sublingual Dosing.....	281
11.3	Steroidal Agents .....	282
11.3.1	Prednisolone and Dexamethasone .....	282
11.4	Adjuvant Enzymes .....	282
11.4.1	Chemophase™ .....	282
11.5	Other Therapies.....	283
11.5.1	Razoxane.....	283
	Further Reading .....	283
	<b>Index.....</b>	<b>285</b>